Director and 10% owner John Simard filed a Form 4 with the SEC on November 13, 2026, reporting the open-market purchase of 70,000 shares of XBiotech Inc. common stock on November 3, 2026.

Key Highlights

  • Reporting person: John Simard, identified in the filing as a Director and 10% Owner of XBiotech Inc. (NASDAQ:XBIT).
  • Transaction: Purchase (transaction code P) of 70,000 shares of common stock on November 3, 2026.
  • Price per share: $2.0487, as stated in the filing.
  • Post-transaction ownership: 4,261,690 shares of common stock held directly following the reported transaction.
  • No derivative securities were reported in Table II of the filing.

Simard's November 2026 Purchase of XBiotech Common Stock

According to the filing, John Simard acquired 70,000 shares of XBiotech Inc. common stock on November 3, 2026, at a price of $2.0487 per share. The transaction is coded "P," indicating an open-market purchase. Simard is identified in the filing as both a Director and a 10% Owner of the issuer, XBiotech Inc., whose shares trade on NASDAQ under the symbol XBIT.

Following the reported transaction, the filing states that Simard directly beneficially owns 4,261,690 shares of XBiotech common stock. The filing was signed by John Simard and dated November 13, 2026, with the date of earliest transaction listed as November 3, 2026. No derivative securities transactions were reported in Table II of the form.

What Was Disclosed

The Form 4 discloses a single open-market purchase by Director and 10% Owner John Simard of 70,000 shares of XBiotech Inc. common stock at $2.0487 per share on November 3, 2026, resulting in direct beneficial ownership of 4,261,690 shares.